Blocking of endogenous MIF by a small molecule such as “ISO-1” and neutralisation of MIF by anti-MIF antibodies or by plant-derived MIF inhibitors reduces the manifestations of inflammatory conditions such as type II collagen-induced arthritis, immunologically induced kidney disease, experimental autoimmune encephalomyelitis, experimental allergic neuritis, immunoinflammatory diabetes, experimental autoimmune myocarditis, irradiation-induced acute pneumonitis, sepsis, and ischemia–reperfusion injury.15–18. This evidence concerns the gene MIF and experimental autoimmune encephalomyelitis.